CN104109708B - 一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 - Google Patents
一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 Download PDFInfo
- Publication number
- CN104109708B CN104109708B CN201310754613.XA CN201310754613A CN104109708B CN 104109708 B CN104109708 B CN 104109708B CN 201310754613 A CN201310754613 A CN 201310754613A CN 104109708 B CN104109708 B CN 104109708B
- Authority
- CN
- China
- Prior art keywords
- small nucleic
- nucleic acids
- nucleic acid
- primer
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 98
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 94
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000012472 biological sample Substances 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 title description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 41
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 230000000295 complement effect Effects 0.000 claims abstract description 14
- 239000002299 complementary DNA Substances 0.000 claims abstract description 8
- 238000010839 reverse transcription Methods 0.000 claims abstract description 7
- 238000012408 PCR amplification Methods 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 19
- 238000010790 dilution Methods 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 229920004890 Triton X-100 Polymers 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 12
- 239000013504 Triton X-100 Substances 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 7
- 238000006384 oligomerization reaction Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 abstract description 18
- 239000002679 microRNA Substances 0.000 abstract description 12
- 108091070501 miRNA Proteins 0.000 abstract description 8
- 108091023037 Aptamer Proteins 0.000 abstract description 3
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 63
- 125000003729 nucleotide group Chemical group 0.000 description 46
- 239000002773 nucleotide Substances 0.000 description 45
- 239000002585 base Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000004445 quantitative analysis Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 125000002652 ribonucleotide group Chemical group 0.000 description 6
- 108091030071 RNAI Proteins 0.000 description 5
- 108091028664 Ribonucleotide Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002336 ribonucleotide Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- -1 antisense Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 102000008682 Argonaute Proteins Human genes 0.000 description 2
- 108010088141 Argonaute Proteins Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
- SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- GFMYEVPBEJFZHH-UHFFFAOYSA-N CP(O)(O)O Chemical compound CP(O)(O)O GFMYEVPBEJFZHH-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000505673 Scintilla Species 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940017687 beta-d-ribose Drugs 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310754613.XA CN104109708B (zh) | 2013-12-31 | 2013-12-31 | 一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310754613.XA CN104109708B (zh) | 2013-12-31 | 2013-12-31 | 一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104109708A CN104109708A (zh) | 2014-10-22 |
CN104109708B true CN104109708B (zh) | 2015-05-13 |
Family
ID=51706696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310754613.XA Active CN104109708B (zh) | 2013-12-31 | 2013-12-31 | 一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104109708B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107385014B (zh) * | 2017-06-13 | 2020-12-22 | 深圳大学 | 一种直接定量检测循环miRNA的RT-qPCR方法 |
WO2021208036A1 (en) * | 2020-04-16 | 2021-10-21 | Singleron (Nanjing) Biotechnologies, Ltd. | A method for detection of whole transcriptome in single cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5192229B2 (ja) * | 2004-04-07 | 2013-05-08 | エクシコン・アクティーゼルスカブ | microRNAおよび低分子干渉RNAの定量化のための新規方法 |
CN102154505B (zh) * | 2011-04-20 | 2013-03-20 | 苟德明 | 一种检测miRNA的方法及引物及其应用 |
CN102676677B (zh) * | 2012-05-16 | 2013-04-10 | 北京旷博生物技术有限公司 | 一种microRNA定量检测方法 |
-
2013
- 2013-12-31 CN CN201310754613.XA patent/CN104109708B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104109708A (zh) | 2014-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230313268A1 (en) | Methods for rna analysis | |
Gagnon et al. | RNAi factors are present and active in human cell nuclei | |
CN1318586C (zh) | 短的双链RNAs的体外合成方法 | |
Petri et al. | Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects | |
EP2337860B1 (en) | Oligonucleotide detection method | |
EP3358014B1 (en) | Method for stabilizing functional nucleic acids | |
JP5766610B2 (ja) | 質量分析法による核酸分子の配列決定 | |
Sepich-Poore et al. | The METTL5-TRMT112 N6-methyladenosine methyltransferase complex regulates mRNA translation via 18S rRNA methylation | |
US8846895B2 (en) | Double-stranded RNA molecules with stability in mammalian body fluid, preparation and application thereof | |
Yang et al. | TENT2, TUT4, and TUT7 selectively regulate miRNA sequence and abundance | |
US20050014264A1 (en) | Method of introducing siRNA into adipocytes | |
EP2401375B1 (en) | Improved design of small-interfering rna | |
CN104109708B (zh) | 一种直接测定生物样品中未经分离的小核酸的方法及检测试剂盒 | |
Yu et al. | Comprehensive analysis of miRNA profiles reveals the role of Schistosoma japonicum miRNAs at different developmental stages | |
CN117677710A (zh) | 用于定量评估mRNA加帽效率的测定 | |
Stratford et al. | Examination of real-time polymerase chain reaction methods for the detection and quantification of modified siRNA | |
Zhang et al. | Conservation of differential animal microRNA processing by Drosha and Dicer | |
Xue et al. | 8-Oxoguanine DNA glycosylase 1 selectively modulates ROS-responsive NF-κB targets through recruitment of MSK1 and phosphorylation of RelA/p65 at Ser276 | |
EP1813289B1 (en) | Medicinal composition for treating cancer or diabetes | |
Xu et al. | Substrate-dependent contribution of double-stranded RNA-binding motifs to ADAR2 function | |
Dedeoğlu et al. | Experimental microRNA targeting validation | |
Thayer et al. | Purity analysis and impurities determination by AEX-HPLC | |
Zhang et al. | The insertion in the double-stranded RNA binding domain of human Drosha is important for its function | |
US20060019298A1 (en) | Sequencing of modified nucleic acid molecules | |
Kim et al. | AQ-seq: Accurate quantification of microRNAs and their variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for directly determining non-separated small nucleic acid in biological sample, and detection kit thereof Effective date of registration: 20180212 Granted publication date: 20150513 Pledgee: Xiamen Park Xisheng equity investment partnership (L.P.) Pledgor: XIAMEN CHENGKUN BIOTECHNOLOGY Co.,Ltd. Registration number: 2018350000021 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181105 Address after: 361101 1-206F, unit 1, Zeng North Road, software park, torch high tech Zone, Xiamen, Fujian Patentee after: Xiamen Park Xisheng equity investment partnership (L.P.) Address before: 361000 4, No. 2036, Weng Kok West Road, Haicang District, Haicang District, Xiamen, Fujian Patentee before: XIAMEN CHENGKUN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: Building 6, Xiaopai Road (Tieshan Park, Longzhou Industrial Park, Fujian), Tieshan Town, Xinluo District, Longyan City, Fujian Province, 364001 Patentee after: Fujian Weijia biomedical Co.,Ltd. Country or region after: China Address before: 361101 1-206F, unit 1, Zeng North Road, software park, torch high tech Zone, Xiamen, Fujian Patentee before: Xiamen Park Xisheng equity investment partnership (L.P.) Country or region before: China |
|
TR01 | Transfer of patent right |